Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425683 · ClinicalTrials.gov registry record · Phase 2
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
A Phase 2 study, sponsored by US Oncology Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02425683: Clinical Trial Phase 2 study, sponsored by US Oncology Research.
NCT02425683 is a Phase 2 study that was terminated before completion, run by US Oncology Research. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02425683, a Phase 2 study, was terminated before completion, sponsored by US Oncology Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX improves treatment, compared to standard of care (SOC), which is no further treatment.
Primary Outcome
To find the starting dose of regorafenib. The first 50 patients will be randomly assigned to receive regorafenib either 120 mg or 160 mg by mouth daily for 1st 21 days of each 28-day cycle for two cycles. Based on safety profile review of adverse events, a final starting dose will be selected for remaining patients assigned to regorafenib.
Interventions
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-03-26 |
| Est. Completion | 2017-09-21 |
| Phase | Phase 2 |
Why NCT02425683 stopped before completion
NCT02425683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which Regorafenib is the first listed.
NCT02425683 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02425683 about?
NCT02425683 is a clinical study titled "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX". This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX improves treatment, compared to standard of care (SOC), which is no fu...
What is the current status of trial NCT02425683?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-03-26. Estimated completion is 2017-09-21.
What interventions are being tested in trial NCT02425683?
The interventions under investigation include: Regorafenib (DRUG).
Who is sponsoring clinical trial NCT02425683?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02425683's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI